Advertisement
Research Article

Relacin, a Novel Antibacterial Agent Targeting the Stringent Response

  • Ezequiel Wexselblatt equal contributor,

    equal contributor Contributed equally to this work with: Ezequiel Wexselblatt, Yaara Oppenheimer-Shaanan, Ilana Kaspy

    Affiliation: Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Yaara Oppenheimer-Shaanan equal contributor,

    equal contributor Contributed equally to this work with: Ezequiel Wexselblatt, Yaara Oppenheimer-Shaanan, Ilana Kaspy

    Affiliation: Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Ilana Kaspy equal contributor,

    equal contributor Contributed equally to this work with: Ezequiel Wexselblatt, Yaara Oppenheimer-Shaanan, Ilana Kaspy

    Affiliation: Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Nir London,

    Affiliation: Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Ora Schueler-Furman,

    Affiliation: Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Eylon Yavin,

    Affiliation: Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Gad Glaser,

    Affiliation: Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Joshua Katzhendler,

    Affiliation: Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Sigal Ben-Yehuda mail

    sigalb@ekmd.huji.ac.il

    Affiliation: Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

    X
  • Published: September 20, 2012
  • DOI: 10.1371/journal.ppat.1002925

About the Authors

Ezequiel Wexselblatt, Eylon Yavin, Joshua Katzhendler
Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
Yaara Oppenheimer-Shaanan, Nir London, Ora Schueler-Furman, Sigal Ben-Yehuda
Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel
Ilana Kaspy, Gad Glaser
Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel

Corresponding Author

Email: sigalb@ekmd.huji.ac.il

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: EW YOS IK NL OSF EY GG JK SBY. Performed the experiments: EW YOS IK NL OSF. Analyzed the data: EW YOS IK NL OSF EY GG JK SBY. Wrote the paper: EW YOS SBY.